MX337469B - Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio. - Google Patents

Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.

Info

Publication number
MX337469B
MX337469B MX2014004738A MX2014004738A MX337469B MX 337469 B MX337469 B MX 337469B MX 2014004738 A MX2014004738 A MX 2014004738A MX 2014004738 A MX2014004738 A MX 2014004738A MX 337469 B MX337469 B MX 337469B
Authority
MX
Mexico
Prior art keywords
phenylimidazol
sodium channel
derivatives useful
channel modulators
ethylamine derivatives
Prior art date
Application number
MX2014004738A
Other languages
English (en)
Spanish (es)
Other versions
MX2014004738A (es
Inventor
Sharanjeet Kaur Bagal
Mark Ian Kemp
Duncan Charles Miller
Yoshihisa Murata
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX337469(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MX2014004738A publication Critical patent/MX2014004738A/es
Publication of MX337469B publication Critical patent/MX337469B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014004738A 2011-10-26 2012-10-15 Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio. MX337469B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (2)

Publication Number Publication Date
MX2014004738A MX2014004738A (es) 2014-08-01
MX337469B true MX337469B (es) 2016-03-02

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004738A MX337469B (es) 2011-10-26 2012-10-15 Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.

Country Status (28)

Country Link
US (1) US9079878B2 (show.php)
EP (1) EP2771335A2 (show.php)
JP (1) JP5946538B2 (show.php)
KR (1) KR101586966B1 (show.php)
CN (1) CN103906746B (show.php)
AP (1) AP2014007579A0 (show.php)
AU (1) AU2012328034B2 (show.php)
BR (1) BR112014009102A2 (show.php)
CA (1) CA2850925C (show.php)
CL (1) CL2014000956A1 (show.php)
CO (1) CO6940427A2 (show.php)
CR (1) CR20140185A (show.php)
CU (1) CU20140046A7 (show.php)
DO (1) DOP2014000085A (show.php)
EA (1) EA023375B1 (show.php)
EC (1) ECSP14013324A (show.php)
GT (1) GT201400079A (show.php)
IL (1) IL232267A (show.php)
MD (1) MD20140037A2 (show.php)
MX (1) MX337469B (show.php)
NI (1) NI201400031A (show.php)
PE (1) PE20141682A1 (show.php)
PH (1) PH12014500919A1 (show.php)
SG (1) SG11201401032YA (show.php)
TN (1) TN2014000147A1 (show.php)
UA (1) UA109220C2 (show.php)
WO (1) WO2013061205A2 (show.php)
ZA (1) ZA201402281B (show.php)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2755980T3 (pl) * 2011-09-14 2020-05-18 Dow Agrosciences Llc Sposoby i układy do wytwarzania kwasów boronowych i ich związków pośrednich
SI3080134T1 (sl) 2013-12-13 2018-11-30 Vertex Pharmaceuticals Incorporated Predzdravila piridon amidov uporabna kot modulatorji natrijevih kanalov
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
JP6779217B2 (ja) * 2014-10-24 2020-11-04 アヴェクタス リミテッド 細胞原形質膜を越える送達方法
KR20170117170A (ko) 2015-02-19 2017-10-20 퍼듀 퍼머 엘피 위 배출을 감소시키기 위한 방법 및 조성물
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017115128A2 (en) 2015-12-30 2017-07-06 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
CA3029132A1 (en) * 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
US11459587B2 (en) 2016-07-06 2022-10-04 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
JP7277431B2 (ja) 2017-07-11 2023-05-19 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのカルボキサミド
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
AR116939A1 (es) 2018-11-02 2021-06-30 Merck Sharp & Dohme 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン-2-カルボキサミド
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CA3256604A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
GEAP202516632A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
EP4511117A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
BRPI0510664B8 (pt) * 2004-05-07 2021-05-25 Warner Lambert Co derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios
AU2005299310A1 (en) * 2004-10-27 2006-05-04 Canji, Inc. Compositions and methods for short interfering nucleic acid inhibition of Nav1.8
HRP20160005T1 (hr) * 2005-12-22 2016-02-12 Newron Pharmaceuticals S.P.A. 2-feniletilamono derivati kao modulatori kalcijskih i/ili natrijskih kanala
SI2076508T1 (sl) 2006-10-18 2011-04-29 Pfizer Prod Inc Spojine biaril eter sečnine
DE602008000809D1 (de) 2007-03-23 2010-04-29 Icagen Inc Ionenkanal-Hemmer
AU2008247102B2 (en) 2007-05-03 2011-11-24 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
US20100227872A1 (en) 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
WO2013061205A3 (en) 2013-06-27
CR20140185A (es) 2014-06-03
CL2014000956A1 (es) 2014-07-18
EP2771335A2 (en) 2014-09-03
NI201400031A (es) 2014-10-01
PE20141682A1 (es) 2014-11-14
PH12014500919A1 (en) 2014-06-09
HK1198650A1 (en) 2015-05-22
IL232267A (en) 2016-10-31
ZA201402281B (en) 2015-11-25
JP5946538B2 (ja) 2016-07-06
CN103906746A (zh) 2014-07-02
WO2013061205A8 (en) 2014-03-27
JP2014530900A (ja) 2014-11-20
EA201490864A1 (ru) 2014-08-29
DOP2014000085A (es) 2014-08-31
AU2012328034A1 (en) 2014-05-15
WO2013061205A2 (en) 2013-05-02
TN2014000147A1 (fr) 2015-09-30
EA023375B1 (ru) 2016-05-31
ECSP14013324A (es) 2014-05-31
CO6940427A2 (es) 2014-05-09
IL232267A0 (en) 2014-06-30
SG11201401032YA (en) 2014-07-30
CA2850925A1 (en) 2013-05-02
US9079878B2 (en) 2015-07-14
CN103906746B (zh) 2015-12-09
KR101586966B1 (ko) 2016-01-19
AP2014007579A0 (en) 2014-04-30
MD20140037A2 (ro) 2014-08-31
CA2850925C (en) 2017-01-10
NZ623090A (en) 2015-10-30
CU20140046A7 (es) 2014-10-02
US20140296313A1 (en) 2014-10-02
MX2014004738A (es) 2014-08-01
AU2012328034B2 (en) 2015-04-23
UA109220C2 (uk) 2015-07-27
GT201400079A (es) 2015-06-02
KR20140069234A (ko) 2014-06-09
BR112014009102A2 (pt) 2017-04-18

Similar Documents

Publication Publication Date Title
PH12014500919A1 (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2009011816A (es) Derivados de piridina.
WO2012007868A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
CR20200157A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
PH12016501028A1 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MY148948A (en) Catecholamine derivatives and prodrugs thereof
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
PH12015502632A1 (en) Cxcr7 receptor modulators
IN2013DN02555A (show.php)
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
IN2014KN00849A (show.php)

Legal Events

Date Code Title Description
FG Grant or registration